



16 October 2024

Results of Extraordinary General Meeting

Melbourne, Australia, 16 October 2024: dorsaVi Limited (ASX: DVL) (**dorsaVi** or the **Company**) provides the following results of its extraordinary general meeting of shareholders in accordance with Listing Rule 3.13.2 and Section 251AA of the Corporations Act.

All resolutions were passed on a poll. Details of resolutions, the proxies received, and the votes cast in respect of each resolution are set out in the attached results summary.

– ENDS –

For further information about dorsaVi, please contact:

Company

Andrew Ronchi
Chief Executive Officer
+61 417 882 267
Email: ar@dorsavi.com

Investors

Joel Seah
Vesparum Capital
+61 3 8582 4800
Email: dorsavi@vesparum.com

This announcement was authorised for release by the Board of dorsaVi.

About dorsaVi

dorsaVi Ltd (ASX: DVL) is an ASX company focused on developing innovative motion analysis device technologies for use in clinical applications, elite sports, and occupational health and safety. dorsaVi believes its wearable sensor technology enables, for the first time, many aspects of detailed human movement and position to be accurately captured, quantified, and assessed outside a biomechanics lab, in both real-time and real situations for up to 24 hours. dorsaVi's focus is on two major markets:

- **Workplace:** dorsaVi enables employers to assess risk of injury for employees as well as test the effectiveness of proposed changes to OHS workplace design, equipment or methods based on objective evidence. dorsaVi works either directly with major corporations, or through an insurance company's customer base with the aim of reducing workplace compensation and claims. dorsaVi has been used by major corporations including Sodexo, London Underground, Vinci Construction, Crown Resorts, Caterpillar (US), Monash Health, Coles, Woolworths, Toll, Toyota, Orora (formerly Amcor) and BHP Billiton.
- **Clinical:** dorsaVi is transforming the management of patients with its clinical solutions (ViMove, ViMove2 and Professional Suite) which provide objective assessment, monitoring outside the clinic and immediate biofeedback. The clinical market is broken down into physical therapy (physiotherapists), hospital in the home and elite sports. Hospital in the home refers to the remote management of patients by clinicians outside of physical therapy (i.e. for orthopaedic conditions). Elite sports refers to the management and optimisation of athletes through objective evidence for decisions on return to play, measurement of biomechanics and immediate biofeedback to enable peak performance.

Further information is available at www.dorsavi.com

The following information is provided in accordance with section 251AA(2) of the Corporations Act 2001 (Cth) and ASX Listing Rule 3.13.2.

Resolution details		Instructions given to validly appointed proxies (as at proxy close)				Number of votes cast on the poll (where applicable)			Resolution Result
Resolution	Resolution Type	For	Against	Proxy's Discretion	Abstain	For	Against	Abstain*	Carried / Not Carried
1 Ratification and approval of prior issue of Tranche 1 Placement Shares	Ordinary	155,591,231 95.32%	619,165 0.38%	7,025,871 4.30%	2,318,181	190,885,196 99.68%	619,165 0.32%	2,318,181	Carried
2 Ratification and approval of prior issue of Tranche 1 Placement Options	Ordinary	155,591,231 95.03%	1,119,165 0.68%	7,025,871 4.29%	1,818,181	190,885,196 99.42%	1,119,165 0.58%	1,818,181	Carried
3A Ratification and approval of prior issue of Lead Manager Options	Ordinary	187,788,091 95.76%	1,285,940 0.66%	7,025,871 3.58%	0	223,082,056 99.43%	1,285,940 0.57%	0	Carried
3B Ratification and approval of prior issue of Consulting Shares	Ordinary	187,788,091 95.79%	1,231,773 0.63%	7,025,871 3.58%	54,167	223,082,056 99.45%	1,231,773 0.55%	54,167	Carried
4 Approval for Issue of Tranche 2 Placement Shares to Unrelated Investors	Ordinary	187,842,258 95.79%	1,231,773 0.63%	7,025,871 3.58%	0	223,136,223 99.45%	1,231,773 0.55%	0	Carried
5 Approval for Issue of Tranche 2 Placement Options	Ordinary	187,954,866 95.85%	1,119,165 0.57%	7,025,871 3.58%	0	223,248,831 99.50%	1,119,165 0.50%	0	Carried
6 Approval of Issue of Placement Securities to Mr Gernot Abl, Director of the Company	Ordinary	187,900,699 95.82%	1,173,332 0.60%	7,025,871 3.58%	0	223,194,664 99.48%	1,173,332 0.52%	0	Carried
7 Approval of Issue of Placement Securities to Dr Andrew Ronchi, Director of the Company	Ordinary	187,900,699 95.82%	1,173,332 0.60%	7,025,871 3.58%	0	197,127,265 99.41%	1,173,332 0.59%	0	Carried
8 Approval of Issue of Placement Securities to Dr Michael Winlo, Director of the Company	Ordinary	187,900,699 95.82%	1,173,332 0.60%	7,025,871 3.58%	0	223,194,664 99.48%	1,173,332 0.52%	0	Carried
9 Approval of Salary Sacrifice Share Plan	Ordinary	185,600,144 96.14%	419,165 0.22%	7,025,871 3.64%	0	193,329,215 99.78%	419,165 0.22%	0	Carried
10 Approval of Issue of Shares to Mr Gernot Abl Pursuant to the Salary Sacrifice Share Plan	Ordinary	185,600,144 96.14%	417,059 0.22%	7,027,977 3.64%	0	193,331,321 99.78%	417,059 0.22%	0	Carried
11 Approval of Issue of Shares to Dr Andrew Ronchi Pursuant to the Salary Sacrifice Share Plan	Ordinary	185,100,144 95.88%	419,165 0.22%	7,525,871 3.90%	0	193,329,215 99.78%	419,165 0.22%	0	Carried
12 Approval of Issue of Shares to Dr Michael Winlo Pursuant to the Salary Sacrifice Share Plan	Ordinary	185,600,144 96.14%	419,165 0.22%	7,025,871 3.64%	0	193,329,215 99.78%	419,165 0.22%	0	Carried
13 Approval of Issue of Shares to Dr Michael Panaccio Pursuant to the Salary Sacrifice Share Plan	Ordinary	185,292,144 95.99%	427,165 0.22%	7,325,871 3.79%	0	193,321,215 99.78%	427,165 0.22%	0	Carried
14 Approval of Issue of Shares to Mr Gernot Abl	Ordinary	188,288,091 96.02%	785,940 0.40%	7,025,871 3.58%	0	223,582,056 99.65%	785,940 0.35%	0	Carried
15 Approval of Issue of Shares to Dr Andrew Ronchi	Ordinary	187,663,118 95.70%	1,410,913 0.72%	7,025,871 3.58%	0	196,889,684 99.29%	1,410,913 0.71%	0	Carried
16 Approval of Issue of Shares to Dr Michael Winlo	Ordinary	188,288,091 96.02%	785,940 0.40%	7,025,871 3.58%	0	223,582,056 99.65%	785,940 0.35%	0	Carried

dorsaVi Ltd
Extraordinary General Meeting
Wednesday, 16 October 2024
Results of Meeting

17 Approval of Issue of Shares to Dr Michael Panaccio	Ordinary	87,698,910 91.81%	793,940 0.83%	7,025,871 7.36%	0	120,792,180 99.35%	793,940 0.65%	0	Carried
---	----------	----------------------	------------------	--------------------	---	-----------------------	------------------	---	---------

* Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll.